Guan Cheng-Nong, Cai Liang-Zhen, Yue Li-Qun, Zhang Ying
Department of Oncology, Affiliated Hospital of Guangdong Medical College, Zhanjiang 524001, China.
Zhongguo Zhong Yao Za Zhi. 2006 Mar;31(6):510-2.
To study the effects of Yanshu injection on the combined treatment in the advanced primary liver cancer.
Eighty-five cases of advanced primary liver cancer were treated with Yanshu injection combining with chemotherapy or only chemotherapy. The curative effects, pain genesic rate, one year survival rate, survival quality of life and cell immune functions were observed.
The remission rate and one year survival rate of the trial group were 60.5% and 51.2%, respectively, and were significantly higher than those (45.2% and 40.5%) of the control group (P < 0.05). The pain relief rate of the trial group was significantly higher than that of the control group (P < 0.05). The improvement of the quality of life was higher than that of the contral group (P < 0.01). The ability of the T-cell subgroup and NK-cell of the trail group were significantly difference between pre-and post-treatment (P < 0.01 or 0.05); however, that of the control group was no obviously change.
Yanshu injection combination with chemotherapy can raise the curative effect, one year survival rate and cellular immune function, reduce pain genesic rate and toxicity of chemotherapy, and improve the quality of life of the patients with advanced primary liver cancer, which is worthy to be recommended for clinical application.
探讨岩舒注射液在晚期原发性肝癌综合治疗中的作用。
将85例晚期原发性肝癌患者分为两组，分别采用岩舒注射液联合化疗及单纯化疗，观察两组疗效、疼痛发生率、1年生存率、生存质量及细胞免疫功能。
试验组缓解率及1年生存率分别为60.5%和51.2%，明显高于对照组的45.2%和40.5%（P<0.05）；试验组疼痛缓解率明显高于对照组（P<0.05）；生活质量改善情况优于对照组（P<0.01）。试验组治疗前后T细胞亚群及NK细胞活性有明显差异（P<0.01或0.05），而对照组无明显变化。
岩舒注射液联合化疗能提高晚期原发性肝癌患者的疗效、1年生存率及细胞免疫功能，降低疼痛发生率及化疗毒性，改善患者生活质量，值得临床推广应用。
